Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
JPRN-jRCT2051260093 Minoxidil Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2051260093 Minoxidil Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
JPRN-jRCT2051260093 clinical trial report covering Minoxidil, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07664553 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07664553 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664553 clinical trial report covering Elecoglipron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07665437 Remibrutinib Hidradenitis Suppurativa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07665437 Remibrutinib Hidradenitis Suppurativa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665437 clinical trial report covering Remibrutinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07669454 Nuvastatic Fatigue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669454 Nuvastatic Fatigue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07669454 clinical trial report covering Nuvastatic, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07665450 Ramantamig Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07665450 Ramantamig Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665450 clinical trial report covering Ramantamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07665476 Cephalexin Cellulitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07665476 Cephalexin Cellulitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665476 clinical trial report covering Cephalexin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262465 Icodextrin Kidney Failure, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262465 Icodextrin Kidney Failure, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262465 clinical trial report covering Icodextrin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07664852 Pramipexole Dihydrochloride Bipolar Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07664852 Pramipexole Dihydrochloride Bipolar Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664852 clinical trial report covering Pramipexole Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
IMD-1828 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
IMD-1828 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
IMD-1828: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
DFI-105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
DFI-105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
DFI-105: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Anti CD 19/22 CAR- T Cells(Medical Visual Systems) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Anti CD 19/22 CAR- T Cells(Medical Visual Systems) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Anti CD 19/22 CAR- T Cells(Medical Visual Systems): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
Read →
GVB-2001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
GVB-2001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
GVB-2001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →